• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Barinthus Biotherapeutics plc

    3/20/25 4:44:29 PM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BRNS alert in real time by email
    S-8 1 tm259819d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on March 20, 2025

    Registration No. 333-       

     

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8 REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

    BARINTHUS BIOTHERAPEUTICS PLC

    (Exact name of registrant as specified in its charter)

     

    England and Wales Not applicable
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification Number)

     

    Unit 6-10, Zeus Building

    Rutherford Avenue

    Harwell, Didcot,

    United Kingdom

      OX11 0DF
    (Address of principal executive offices)   (Zip Code)

     

    Share Award Plan 2021

    2021 Employee Share Purchase Plan

    (Full Title of the Plans)

     

    William Enright

    President

    Barinthus Biotherapeutics North America, Inc.

    855 N. Wolfe Street, Suite 102

    Baltimore, MD 21205

    +1 (410) 916-7930

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Robert E. Puopolo Andrew Harrow 
    Marishka DeToy Goodwin Procter (UK) LLP
    Goodwin Procter LLP 100 Cheapside
    100 Northern Avenue London EC2V 6DY
    Boston, MA 02210 United Kingdom
    (617) 570-1000 +44 20 7447 4200

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer ¨
           
    Non-accelerated filer x Smaller reporting company x
           
        Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 relating to the Share Award Plan 2021 (the “2021 Plan”) and the 2021 Employee Share Purchase Plan (the “2021 ESPP”) of Barinthus Biotherapeutics plc (the “Registrant”) registers additional securities of the same class as other securities for which registration statements filed on Form S-8 (SEC File No. 333-255664, SEC File No. 333-263844, SEC File No. 333-270815 and SEC File No. 333-278111) of the Registrant are effective. Accordingly, the information contained in the Registrant’s registration statements on Form S-8 (SEC File No. 333-255664, SEC File No. 333-263844, SEC File No. 333-270815 and SEC File No. 333-278111) filed with the Securities and Exchange Commission on April 30, 2021, March 25, 2022, March 24, 2023 and March 20, 2024, respectively, is hereby incorporated by reference pursuant to General Instruction E.

     

    The number of securities reserved and available for issuance under the 2021 Plan is subject to an automatic annual increase on each January 1 by an amount equal to the lesser of: (i) 4.0% of the issued and outstanding ordinary shares as of January 1 of such year, or (ii) such amount as determined by the Compensation Committee of the Registrant’s Board of Directors. Accordingly, on January 1, 2025, the number of ordinary shares reserved and available for issuance under the 2021 Plan increased by 1,609,386 shares. The number of securities reserved and available for issuance under the 2021 ESPP is also subject to an automatic annual increase on each January 1, beginning in 2022, by an amount equal to the lesser of: (i) 735,136 Shares, (ii) 1.0% of the amount of ordinary shares issued and outstanding on the immediately preceding December 31, or (iii) such lesser number of ordinary shares determined by the Compensation Committee of the Registrant’s Board of Directors. Accordingly, on January 1, 2025, the number of ordinary shares reserved and available for issuance under the 2021 ESPP increased by 402,346 shares.

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    See the Exhibit Index for a list of exhibits filed as part of this Registration Statement, which Exhibit Index is incorporated herein by reference.

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
         
    5.1 *  Opinion of Goodwin Procter (UK) LLP, counsel to the Registrant.
    23.1 *  Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.
    23.2 *  Consent of Goodwin Procter (UK) LLP, counsel to Registrant, (included in Exhibit 5.1).
    24.1 *   Power of Attorney (included on signature page to this registration statement).
    107*   Filing Fee Table

     

    *            Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Village of Harwell, United Kingdom, on the 20th day of March, 2025.

     

      BARINTHUS BIOTHERAPEUTICS PLC
       
      By:   /s/ William Enright
        William Enright
        Chief Executive Officer

     

     

     

     

    POWER OF ATTORNEY AND SIGNATURES

     

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of William Enright and Gemma Brown as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney- in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.

     

      Name Title Date
           
      /s/ William Enright Chief Executive Officer and Director March 20, 2025
      William Enright (Principal Executive Officer)  
           
      /s/ Gemma Brown Chief Financial Officer March 20, 2025
      Gemma Brown (Principal Financial Officer and Principal Accounting Officer)  
           
      /s/ Robin Wright Chairman of the Board of Directors March 20, 2025
      Robin Wright    
           
      /s/ Alex Hammacher Director March 20, 2025
      Alex Hammacher    
           
      /s/ Pierre Morgon Director March 20, 2025
      Pierre Morgon    
           
      /s/ Dr. Anne M. Phillips Director March 20, 2025
      Dr. Anne M. Phillips    
           
      /s/ Karen T. Dawes Director March 20, 2025
      Karen T. Dawes    
           
      /s/ Dr. Joseph C. F. Scheeren Director March 20, 2025
      Dr. Joseph C. F. Scheeren    
           
    By: /s/ William Enright Authorized Representative in the United States March 20, 2025
    Name: William Enright    

     

     

     

    Get the next $BRNS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BRNS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BRNS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments

      Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025;Initiation of VTP-1000 multiple ascending dose expected in the second half of 2025; Encouraging results from HBV003 and IM-PROVE II presented at EASL, supporting ongoing partnering efforts; Available resources expected to provide a cash runway into 2027. OXFORD, United Kingdom and GERMANTOWN, Md., May 07, 2025 (GLOBE NEWSWIRE) --  Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation ("I&I") company focused on developing therapies that promote immune tolerance

      5/7/25 8:00:00 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

      Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000) in the clinic, with first data expected in third quarter of 2025Proprietary SNAP-TI platform promoting antigen-specific immune tolerance is anticipated to drive multiple future pipeline and partnership opportunities Strategic prioritization of resources expected to provide a cash runway into 2027 OXFORD, United Kingdom and GERMANTOWN, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation (I&

      3/20/25 7:22:19 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

      Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identifiedExtending the cash runway to the start of 2027 by reducing costs, including an approximate 65% reduction in workforce and expected closure of the U.K. site Future operations will be focused at the U.S. site in Germantown, Maryland OXFORD, United Kingdom and GERMANTOWN, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), today provided a strategic business and financial update. Barinthus Bio is a clinical-stage biopharmaceutical co

      1/10/25 8:00:00 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BRNS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Barinthus Biotherapeutics plc

      10-Q - Barinthus Biotherapeutics plc. (0001828185) (Filer)

      5/7/25 8:12:43 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barinthus Biotherapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)

      5/7/25 8:10:46 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Barinthus Biotherapeutics plc

      DEFA14A - Barinthus Biotherapeutics plc. (0001828185) (Filer)

      4/25/25 4:14:15 PM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BRNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Brown Gemma

      4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)

      2/5/25 4:24:43 PM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Enright William

      4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)

      2/5/25 4:24:31 PM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Business Officer Griffiths Graham

      4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)

      2/5/25 4:24:18 PM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BRNS
    Leadership Updates

    Live Leadership Updates

    See more
    • Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

      OXFORD, United Kingdom and GERMANTOWN, Md., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio"), today announced the promotion of Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer (CSO), effective as of December 1, 2024. Dr. Lynn succeeds Nadège Pelletier, Ph.D. who decided to pursue alternative opportunities closer to home after having served as Barinthus Bio's CSO since early 2023. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease. "Dr. Pelletier's strong vision and leadership have resulted in a robust preclinical pipeline of promising leads for

      11/25/24 4:01:00 PM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

      OXFORD, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, today announced the appointment of Leon Hooftman, M.D., as Chief Medical Officer (CMO). "We are happy to welcome Dr. Hooftman to Barinthus Bio as our Chief Medical Officer. With his experience spearheading clinical studies from early development through late-stage trials, he is a valuable addition to the Barinthus Bio team during a critical time in our growth," said Chi

      5/1/24 7:00:00 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BRNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $BRNS
    Financials

    Live finance-specific insights

    See more
    • Amendment: SEC Form SC 13G/A filed by Barinthus Biotherapeutics plc

      SC 13G/A - Barinthus Biotherapeutics plc. (0001828185) (Subject)

      11/1/24 11:20:26 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Barinthus Biotherapeutics plc

      SC 13G - Barinthus Biotherapeutics plc. (0001828185) (Subject)

      10/15/24 11:07:21 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments

      Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025;Initiation of VTP-1000 multiple ascending dose expected in the second half of 2025; Encouraging results from HBV003 and IM-PROVE II presented at EASL, supporting ongoing partnering efforts; Available resources expected to provide a cash runway into 2027. OXFORD, United Kingdom and GERMANTOWN, Md., May 07, 2025 (GLOBE NEWSWIRE) --  Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation ("I&I") company focused on developing therapies that promote immune tolerance

      5/7/25 8:00:00 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

      Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000) in the clinic, with first data expected in third quarter of 2025Proprietary SNAP-TI platform promoting antigen-specific immune tolerance is anticipated to drive multiple future pipeline and partnership opportunities Strategic prioritization of resources expected to provide a cash runway into 2027 OXFORD, United Kingdom and GERMANTOWN, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation (I&

      3/20/25 7:22:19 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results

      OXFORD, United Kingdom, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates, provided an overview of the Company's progress and announced its financial results for the second quarter of 2024. "Following the positive VTP-300 Phase 2 data in hepatitis B virus (HBV) in the second quarter, we made the strategic decision to prioritize our HBV and celiac disease programs. These two programs have the greatest probability for success and value creation, and represent significant opportunities in therapeutic areas with substantial unmet patient need," said Bill Enright, Chief

      8/8/24 8:00:00 AM ET
      $BRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care